From Cold to Hot: Leveraging RNA Splicing Therapeutics to Unleash Antitumor Immunity for Breast Cancer Patients
Abstract
Although immune checkpoint blockade therapy (ICBT) emerged as an effective treatment on a subset of breast cancer patients, it remains a daunting challenge to make more patients respond. Our preliminary studies suggest that inhibition of splicing, a process to join the protein-coding parts of RNAs during gene expression, leads to immunostimulatory responses in triple negative breast cancers (TNBCs). We hypothesized that splicing inhibition accumulates mis-spliced RNAs, which may activate innate immune responses and lead to expression of neoantigens. In this application, we aim to test this hypothesis and examine if a clinically available splicing inhibitor can synergize with ICBT in immunocompetent models. We will also elucidate specific immune cells that may mediate such synergy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2019
- Accession Number
- AD1089960
Entities
People
- Xiang Zhang
Organizations
- Baylor College of Medicine